Bausch + Lomb Corp stock sees modest gains amid mixed market sentiment.
Bausch + Lomb Corp (BLCO.TO) experienced a slight uptick of 1.07% in today's trading session, closing at C$23.07. Over the past week, the stock has shown a minimal increase of 0.13%, reflecting cautious investor sentiment. As the health care sector continues to navigate challenges, Bausch + Lomb remains in the spotlight with recent developments.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.10B
52W high
$25.70
52W low
$18.24
1W change
+0.13%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to fall 17.0% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.85
-17.0% Upside
Current Price
C$22.72
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
33.3%
Annualized
90-Day Vol
30.1%
Annualized
Trend (90d)
+32.7%
Annualized drift
90d Mean
C$25.53
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$23.62 | C$21.06 – C$26.49 |
| 60 trading days | C$24.56 | C$20.88 – C$28.88 |
| 90 trading days | C$25.53 | C$20.93 – C$31.14 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of both the company's recent product launches and the overall bearish analyst outlook when evaluating Bausch + Lomb's stock performance.
C$23.07 closing price, reflecting a 1D gain of 1.07%.
Bausch + Lomb's stock is currently trading at 65% of its 52-week range, indicating room for movement within the established price band.
Bull case
The recent launch of the EyeGility Inserter for enVista IOLs could strengthen Bausch + Lomb's position in the ophthalmology market, potentially driving revenue growth in the future.
Bear case
Analysts have a bearish outlook, with an average target price significantly lower than the current trading price. This suggests challenges ahead for Bausch + Lomb in achieving profitability.
Recent Price Action
Bausch + Lomb Corp (BLCO.TO) closed today at C$23.07, up 1.07% from the previous trading day. Over the past week, the stock has seen a slight increase of 0.13%. Year-to-date, it has dipped by 0.31%, highlighting a relatively stable but cautious investor sentiment in the health care sector.
Company News and Catalysts
Recent headlines surrounding Bausch + Lomb include the launch of the EyeGility Inserter for enVista IOLs in the U.S., which could contribute to the company’s growth in the ophthalmology devices market. Analysts at RBC have noted that the growth of Bausch + Lomb's prescription drug segment may support positive results in the upcoming Q2 earnings report. However, some analysts have expressed concerns, advising investors to reconsider their positions amid a bearish outlook.
Technical Picture
Bausch + Lomb's stock is currently trading at C$23.07, with a 50-day moving average of C$22.19 and a 200-day moving average of C$22.56. The stock has a beta of 0.56, indicating lower volatility compared to the broader market. Its 52-week trading range has been between C$18.24 and C$25.70, suggesting that the stock is currently at 65% of its 52-week range. Volume today was 301 shares, which is 0.76 times the 20-day average volume of 2,250 shares.
Advertisement
Wealth Awesome Newsroom
The Wealth Awesome Newsroom delivers timely Canadian market updates, earnings, dividends, and stock movers for DIY investors. Coverage is reviewed against public filings and market data feeds.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
